Breaking News: MediPharm Labs and Hybrid Pharm Partner to Offer New Same Day Registration and Delivery Service of Medical Cannabis | Financial Buzz

Breaking News: MediPharm Labs and Hybrid Pharm Partner to Offer New Same Day Registration and Delivery Service of Medical Cannabis

MediPharm Labs Corp. (OTCQX: MEDIF) (TSX: LABS) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced it will supply premium, pharmaceutical-quality cannabis products to Hybrid Pharm Inc. (“Hybrid Pharm”), a modern wellness pharmacy and medical cannabis sales licence holder serving patients in the Ottawa region.

Partnering with MediPharm Labs as a trusted supplier, Hybrid Pharm is unique among pharmacies in Canada in that it provides medical cannabis patients with a full in-store experience including consultation services. Hybrid Pharm’s qualified pharmacists work closely with healthcare practitioners to provide same day registration and delivery, as well as drug interaction checks and continuous care monitoring.

According to the Ontario College of Pharmacists, patients should expect their pharmacy professional to have the knowledge to assist patients who may be using cannabis to help them make the best decisions about their care to meet their needs or health goals. Pharmacy professionals are often the most accessible healthcare providers for patients and therefore have an opportunity to provide additional support and education related to the use of cannabis as it relates to a patient’s overall pharmacy care, experience and outcomes, such as helping to educate patients on known interactions of cannabis with other medications.

“Medical cannabis users value the brand-name, pharma-quality products that MediPharm Labs provides through our GMP-certified Canadian production facility, but they also crave the touch that only pharmacists and their staff can deliver and that’s what patients receive at Hybrid Pharm,” said Pat McCutcheon, Chief Executive Officer of MediPharm Labs. “We believe Hybrid Pharm’s approach to patient care aligns perfectly with our own philosophy and we are delighted to be chosen as a key supplier.”

Like any other drug, medical cannabis is best dispensed by qualified pharmacists who are equipped to help patients learn about strains, dosage forms and side effects. Hybrid Pharm took this into account when establishing its presence in the marketplace and creating informative patient workshops and seminars that are attended by first-time and long-time consumers alike. “Patients deserve an outlet to discuss their medical needs. Recreational cannabis stores are not qualified to provide medical advice,” says Dr. Rahim Dhalla, Chief Executive Officer of Hybrid Pharm.

Hybrid Pharm believes its in-store approach will eventually become the standard among Canadian pharmacies dispensing medical cannabis.

“As a full-service pharmacy dedicated to patient safety, we have very deliberately chosen to carry only trusted cannabis products that we can recommend with confidence and that’s exactly why we sought out MediPharm Labs as a supplier,” said Dr. Dhalla. “Not only do they meet all of the qualifications we look for including GMP-certified production processes, their state-of-the-art facility is right here in Ontario which means reliable supply of branded formulations for our rapidly growing patient base. We look forward to a long and productive relationship.”

Under the renewable one-year agreement, MediPharm Labs will provide its own CBD25:5 Release Formula and CBD50 Plus Formula introduced this spring, as well as special formulations of branded vaporizers to be sold by Hybrid Pharm.

About Hybrid Pharm

Hybrid Pharm is one of Canada’s first compounding pharmacies specializing in medical cannabis. Located in Ottawa, Hybrid Pharm provides a multi-modal approach to healthcare including traditional pharmacy services, compounding, medical cannabis and over-the-counter wellness and lifestyle modification programming. Hybrid Pharm’s goal is to provide a higher quality experience and therefore a higher quality of life for our patients. Using traditional and non-traditional methods, we embody a balanced approach to treat the mind, the body, and the soul. Please visit for more information.

About MediPharm Labs

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and is nearing commercialization of its Australian extraction facility. MediPharm Labs Australia was established in 2017.

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For medipharm labs corp., investor relations, video production, filming editing, news reporting, financial and corporate news dissemination, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: